or Try an Advanced Search...

    Technical Analysis for ROIV - Roivant Sciences Ltd.

    Grade Last Price % Change Price Change
    C 10.83 2.46% 0.26
    ROIV closed up 2.46 percent on Monday, July 1, 2024, on 84 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical ROIV trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    20 DMA Resistance Bearish 2.46%
    MACD Bearish Signal Line Cross Bearish 2.46%
    200 DMA Support Bullish 2.46%
    Bollinger Band Squeeze Range Contraction 2.46%
    200 DMA Support Bullish 2.46%
    Bollinger Band Squeeze Range Contraction 2.46%
    Older End-of-Day Signals for ROIV ...

       Recent Intraday Alerts

    Alert Time
    Up 1 ATR about 4 hours ago
    60 Minute Opening Range Breakout about 8 hours ago
    20 DMA Resistance about 9 hours ago
    10 DMA Resistance about 9 hours ago
    Up 2% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ROIV Chart by TradingView
    Basic chart:

    Profile

    Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Autoimmune Disease Antibodies Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis

    Is ROIV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 2 Roivant Sciences: Executing On Huge Buyback Program With More To Come
    May 30 Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
    May 30 Roivant Sciences GAAP EPS of -$0.19 beats by $0.11, revenue of $28.93M misses by $2.01M
    May 30 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
    May 29 Roivant Sciences Q4 2024 Earnings Preview
    May 22 Vivek Ramaswamy Breathes New Life In Beaten Down BuzzFeed Stock: What's Going On?
    May 16 Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
    May 5 Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
    Apr 24 Roivant Sciences: Cashing In On Vants And Ventures
    Apr 2 Roivant announces $1.5B share buyback, positive Phase 2 data
    See more ROIV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.24
    52 Week Low 8.245
    Average Volume 4,887,258
    200-Day Moving Average 10.54
    50-Day Moving Average 10.93
    20-Day Moving Average 10.72
    10-Day Moving Average 10.73
    Average True Range 0.31
    RSI (14) 51.46
    ADX 16.17
    +DI 18.51
    -DI 21.60
    Chandelier Exit (Long, 3 ATRs) 10.27
    Chandelier Exit (Short, 3 ATRs) 11.12
    Upper Bollinger Bands 10.98
    Lower Bollinger Band 10.46
    Percent B (%b) 0.72
    BandWidth 4.80
    MACD Line -0.06
    MACD Signal Line -0.07
    MACD Histogram 0.01
    Fundamentals Value
    Market Cap 8.71 Billion
    Num Shares 804 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -7.37
    Price-to-Sales 84.25
    Price-to-Book 8.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.42
    Resistance 3 (R3) 11.37 11.13 11.32
    Resistance 2 (R2) 11.13 10.98 11.15 11.28
    Resistance 1 (R1) 10.98 10.89 11.06 11.03 11.25
    Pivot Point 10.74 10.74 10.78 10.76 10.74
    Support 1 (S1) 10.59 10.59 10.67 10.64 10.41
    Support 2 (S2) 10.35 10.50 10.37 10.38
    Support 3 (S3) 10.20 10.35 10.34
    Support 4 (S4) 10.25